Earlier this week, shares of Zeltia soared almost 3% after the company announced that it has initiated U.S. clinical trial of a new antitumor product. Noscira also one of its subsidiaries reported in late January that it had attracted 19 million euros in capital increase and that it had input for the first time since its creation in public investment funds specializing in biotechnology.
Meanwhile, the biotechnology industry is experiencing a busy start to the year in the offensive launched by Sanofis-Aventis to take over the U.S. biotechnology company Genzyme. Other values of the Spanish market as Grifols, Rovi-Faes Farma or Almirall remain a target for investors.
In the light of this news begs the question is it a good time to enter Zeltia or some of these companies in the pharmaceutical industry? Are there opportunities in mutual funds that invest in these securities? What medical news on the horizon of these companies you can shoot or break your trading? Will it still be hurting the poor sales of drugs against Influenza A accounts for some of the large conglomerates in the sector?
To answer these questions, INVERTIA available to users with DOCTOR today Thursday, February 10 (however, the answers will start running after 13 hours) up to 13 hours of mñana Friday 11 February. Responsible for responding to questions from investors will be the expert Miguel Méndez, Brokerhouse Hanseatic analyst. It will do so through this blog thread, so to send your question need not be registered in Invertia but only to make a comment about the post. Will be published immediately and progressively answered by our expert. All content is monitored by the content team Invertia.